EFG Asset Management North America Corp. Buys 37,061 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

EFG Asset Management North America Corp. increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 99.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,190 shares of the biopharmaceutical company’s stock after acquiring an additional 37,061 shares during the quarter. Intra-Cellular Therapies makes up 0.8% of EFG Asset Management North America Corp.’s investment portfolio, making the stock its 24th largest position. EFG Asset Management North America Corp.’s holdings in Intra-Cellular Therapies were worth $6,200,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of ITCI. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the third quarter valued at approximately $32,000. GAMMA Investing LLC boosted its position in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 240 shares during the period. Venturi Wealth Management LLC bought a new stake in Intra-Cellular Therapies in the 4th quarter worth $96,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Intra-Cellular Therapies in the third quarter valued at about $97,000. Finally, Quarry LP raised its stake in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 1,300 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research report on Thursday, March 20th. They issued a “hold” rating for the company. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.70 on Tuesday. The firm has a 50 day moving average price of $128.70 and a 200-day moving average price of $98.18. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.71. The firm has a market capitalization of $14.00 billion, a price-to-earnings ratio of -151.38 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.